In December 2022, Moderna signed a 10-year strategic partnership with the UK government to enhance pandemic preparedness and provide the UK public with direct access to mRNA vaccines.
The Moderna Innovation and Technology Centre (MITC) is a core element of this unique partnership, with the ability to produce up to 100 million doses of respiratory vaccines per year, and up to 250 million in the event of a pandemic.

The MITC consists of a Drug Substance Manufacturing Facility and a Clinical Research & Development (R&D) Facility.

This is the Drug Substance Manufacturing Facility, which is where we manufacture mRNA vaccines for respiratory viruses such as COVID-19 and respiratory syncytial virus (RSV)
.
There is a three-step process involved in vaccine production here at the MITC: manufacture, test and release.